The nourishing, protective magic of shrooms

We're not ones to gatekeep and neither is Mother Nature — one of her best-kept secrets comes bottled in Origins' powerhouse Mega-Mushroom range, which helps soothe, restore and fortify skin.
Harnessing the magic of medicinal mushrooms such as reishi, fermented chaga and tremella, the Restorative Skin Concentrate with a Phyto-Powered Barrier Defence Complex lets you say bye-bye to irritated, sensitive skin. It strengthens and supports the skin's barrier while leaving it super hydrated and luminous.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

South Wales Argus

3 minutes ago

• South Wales Argus

Rogerstone: Four-bed detached house in Alcan Grove for sale

The property, listed by Davis & Sons, boasts a large living room, study, utility room, conservatory, and a spacious kitchen diner. There is also an en-suite attached to the master bedroom, and another to the second bedroom. The property also features an entrance hall, utility room, and a downstairs WC. The conservatory (Image: Davis & Sons) The property has a large evergreen rear garden, a spacious lawn area, and a patio seating area. There is also a double driveway and garage to the front, providing ample off-street parking. The house is situated in a quiet residential area, close to local amenities, schools, and transport links. Rogerstone, a suburban village in Newport, blends historic charm with modern convenience. One of the bedrooms (Image: Davis & Sons) It offers well-regarded schools, green spaces like the Fourteen Locks Canal Centre, and regular rail links to Newport and Cardiff via Rogerstone station. With easy access to the M4, it is a popular choice for families and commuters seeking a strong community feel with excellent transport connections. The agency states: "This property is not to be missed." To arrange a viewing, contact the Newport head office or reach out via email.

Yahoo

4 minutes ago

• Yahoo

Alex Pereira: Focus on Magomed Ankalaev rematch, not heavyweight move

NEW YORK—Fans clamoring for Alex Pereira to move to heavyweight are going to have to wait a bit longer. Pereira dropped the UFC light heavyweight title to Magomed Ankalaev in the main event of UFC 313 in March. With the heavyweight division up in the air, Jon Jones saying multiple times he's not interested in fighting right now, and interim champ Tom Aspinall looking for an opponent, 'Poatan' would be a popular choice to flip one of the UFC's thinner divisions upside down. Advertisement That time is not now, however, as Pereira has his sights set on a fall return to avenge his loss to Ankalaev. 'Anywhere around the timeframe [of] September, October, November, for me it makes no difference, I want to fight,' Pereira told MMA Fighting at Fanatics Fest. 'My focus right now is fighting Ankalaev... get my belt back, and then we see what happens after.' Pereira has accomplished so much in so little time that the opportunity to win a third divisional title seems like a reasonable goal and request. Right now, Pereira hopes the heavyweight division can get moving again in an entertaining way, but he has his own boxes to check. Advertisement 'Let those guys kill each other in that weight class,' Pereira said. 'Right now I'm just focusing on light heavyweight.' More from

The Independent

4 minutes ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.